Peptides for Skin & Hair: GHK-Cu, Topical Claims and What Actually Has Evidence

Peptides for Skin & Hair · What Holds Up

By Jamie Walston · Beverly Hills Rejuvenation Center · Reviewed by the BHRC Clinical Team

Cosmetic peptides get to make appearance claims because they are cosmetics. For hair, the two things with real approval data are unglamorous — and they work.

1. The line between a cosmetic and a drug

This distinction explains almost everything about how topical peptides are marketed, so it is worth getting straight.

Under the Food, Drug and Cosmetic Act, a cosmetic is a product intended for cleansing, beautifying, promoting attractiveness or altering appearance. A drug is a product intended to affect the structure or any function of the body, or to treat or prevent disease. Cosmetics require no FDA premarket approval. Drugs do.

The consequence: a topical peptide serum can say it makes skin look firmer. The moment it claims to build collagen — a structural change — it has made a drug claim about an unapproved drug. This is why cosmetic copy reads the way it does, and why “clinically proven to reduce the appearance of fine lines” is a carefully constructed sentence rather than a sloppy one.

2. GHK-Cu — real biochemistry, uncertain topical outcome

GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper. Copper is a cofactor for lysyl oxidase, an enzyme central to collagen and elastin cross-linking, and the GHK-Cu complex has a substantial preclinical literature around wound healing and matrix remodelling.

That is genuinely interesting biochemistry. It is also not the same as a demonstrated cosmetic outcome in human skin from a topical product at a cosmetic concentration. The gap between the two is where most of the marketing lives.

On the injectable side, GHK-Cu was among the twelve peptides the FDA removed from Category 2 in April 2026 — a removal that happened because the nominations were withdrawn, not because the agency cleared anything on safety. Removal from Category 2 does not make a substance eligible for compounding under section 503A, and injectable GHK-Cu is not on the 503A bulks list. We wrote about that whole shift in our guide to the 2026 reclassification and covered GHK-Cu’s place in a marketed blend in our review of the Glow protocol.

3. The other topical peptides you will see

Cosmetic peptides are usually grouped by proposed mechanism. A brief, honest map:

The “neurotransmitter-inhibiting” category — acetyl hexapeptide-8, marketed as a topical alternative to neurotoxin — deserves a specific note. The proposed mechanism involves interfering with vesicle docking at the neuromuscular junction. Whether a topical application delivers a meaningful amount of peptide to a motor nerve terminal beneath the dermis is exactly the penetration question above, and the honest answer is that it is not established. If a product genuinely produced the effect it is named for, it would be a drug. It is sold as a cosmetic.

4. Hair: what is approved, and where everything else sits

Only two drugs hold FDA approval for androgenetic alopecia, and the gap between their evidence base and everything else is very large.

Topical minoxidil. The 2% solution was approved in 1988 and switched to over-the-counter in February 1996; the 5% solution was approved in 1997. The label is specific about what it does and does not do: it treats the vertex — the top of the scalp — not a receding hairline. Results “may occur at 2 months with twice a day usage,” and for some men take at least four months. And the label is blunt about dependence: “Continued use is necessary to increase and keep your hair regrowth or hair loss will begin again.”

Oral finasteride 1 mg. Approved December 1997, indicated for male pattern hair loss in men only. The registration data is the strongest in this field: at twelve months, a 107-hair difference from placebo within a one-inch-diameter circle, across roughly 1,350 men; at twenty-four months, a 138-hair difference.

Low-level laser therapy devices — caps, combs, helmets — are 510(k)-cleared, not approved. The first was cleared in January 2007. The classification describes use three times weekly for a minimum of 26 weeks. Say “FDA-cleared,” never “FDA-approved,” for any of them.

Two things worth knowing that clinics often blur: there is no FDA-approved topical finasteride in the United States — every approved finasteride product is oral, so any topical is compounded and unapproved. And oral minoxidil is not approved for hair loss: approved minoxidil tablets carry a boxed warning and are indicated only for severe refractory hypertension. Low-dose oral minoxidil for hair is entirely off-label.

5. Where PRP fits

PRP is the most common in-clinic adjunct for hair, and the evidence is real but qualified. A 2024 meta-analysis of fourteen randomized trials found a mean increase of +27.55 hairs per square centimetre — while rating the certainty low and noting the studies were “highly heterogeneous, of low quality, and presented evident publication bias.” The effect on hair diameter was not significant.

An American Family Physician review noted that in indirect network comparison PRP outperformed minoxidil and 5-alpha-reductase inhibitors — but that only minoxidil had high-quality evidence, and PRP did not beat low-level laser therapy. The defensible position: PRP is a reasonable adjunct with low-certainty evidence, no approved indication, no standardised protocol and no durability data. It is not a replacement for approved therapy, and anyone presenting it as one is overstating it.

Full detail and pricing are in our hair restoration page and in the regenerative therapies guide.

6. What we would actually suggest

• Start with what has a label. For hair, that means minoxidil and — after a real conversation about the label — potentially finasteride. Adjuncts layer on top of those, not instead.
• Rule out the treatable causes first. Thyroid dysfunction, iron deficiency and genuine hormone deficiency all present as hair loss and all have specific treatments. A baseline panel is the least glamorous and most useful first step.
• For skin, retinoids and sunscreen still outperform every peptide serum on the market on evidence quality. That has not changed.
• Judge a topical peptide on its formulation, not its ingredient list. The molecule is the easy part; delivery is the hard part, and almost nobody publishes data on it.
• Treat “FDA-cleared” and “FDA-approved” as different words. They are.

An interesting mechanism is a reason to study something. It is not, on its own, a reason to buy it.

Questions we get asked

Keep reading

• GHK-Cu at BHRC — the copper peptide page
• The Glow protocol — GHK-Cu, BPC-157 and TB-500 reviewed
• Hair restoration at BHRC Paradise Valley
• PRP and PRF at BHRC
• The 2026 FDA peptide reclassification, explained
• Aging skin — the treatments with the best evidence
• Advanced lab testing — ruling out treatable causes

Book at any of our six locations

References

1. U.S. Food and Drug Administration — Is it a cosmetic, a drug, or both? (or is it soap?) — the statutory definitions and how intended use determines category. fda.gov
2. U.S. Food and Drug Administration — PROPECIA (finasteride) tablets prescribing information, NDA 020788 — efficacy data and postmarketing safety reports. accessdata.fda.gov
3. U.S. Food and Drug Administration — Drugs@FDA — NDA 019501, ROGAINE (minoxidil 2% topical solution), approved 1988, Rx-to-OTC switch 1996. accessdata.fda.gov
4. U.S. Food and Drug Administration — Product classification — product code OAP, laser comb for hair, 21 CFR 890.5500 (510(k)-cleared, not approved). accessdata.fda.gov
5. Kieling L, Konzen AT, Zanella RK, Valente DS — Is autologous PRP capable of increasing hair density in androgenic alopecia? A systematic review and meta-analysis. An Bras Dermatol 2024;99(6):847–862. anaisdedermatologia.org.br
6. Georgiadis J, Phillips JH, Mott T — Platelet-rich plasma for androgenic alopecia. Am Fam Physician 2022;105(1):84–85 — network comparison and evidence quality. aafp.org
7. U.S. Food and Drug Administration — Certain bulk drug substances for use in compounding that may present significant safety risks — including the April 2026 withdrawn-nomination table. fda.gov
8. Cornell Legal Information Institute — 21 CFR § 216.23 — the 503A bulks list. law.cornell.edu

Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. Topical peptide products are regulated as cosmetics and are not FDA-approved to treat any condition. Injectable GHK-Cu is not on either FDA compounding bulks list. Finasteride is indicated in men only and carries significant labeled safety information. Candidacy, dosing, results and pricing vary by person and are confirmed at a free consultation. Reviewed by the BHRC clinical team.